Tetrazoles

"Tetrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

No definition found.

Descriptor ID	D013777
MeSH Number(s)	D03.383.129.617
Concept/Terms	Tetrazoles Tetrazoles

Below are MeSH descriptors whose meaning is more general than "Tetrazoles".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Tetrazoles [D03.383.129.617]

Below are MeSH descriptors whose meaning is related to "Tetrazoles".

Below are MeSH descriptors whose meaning is more specific than "Tetrazoles".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tetrazoles" by people in this website by year, and whether "Tetrazoles" was a major or minor topic of these publications.

Bar chart showing 267 publications over 27 distinct years, with a maximum of 20 publications in 2006 and 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	1	0	1
1994	1	1	2
1997	3	0	3
1998	3	0	3
1999	3	0	3
2000	3	0	3
2001	4	3	7
2002	1	0	1
2003	7	0	7
2004	8	2	10
2005	11	3	14
2006	12	8	20
2007	10	5	15
2008	9	11	20
2009	6	2	8
2010	8	7	15
2011	5	2	7
2012	6	3	9
2013	5	4	9
2014	13	4	17
2015	11	2	13
2016	17	1	18
2017	14	2	16
2018	7	5	12
2019	14	3	17
2020	4	9	13
2021	0	4	4

Below are the most recent publications written about "Tetrazoles" by people in Profiles.

Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021 06; 23(6):882-894.

View in: PubMed
Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, Guo W, Zhou Y, Lefkowitz M, Gong J, Wang Y, Merkely B, Macin SM, Shah U, Nicolau JC, Braunwald E. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021 06; 23(6):1040-1048.

View in: PubMed
Martyn T, Faulkenberg KD, Albert CL, Il'giovine ZJ, Randhawa VK, Donnellan E, Menon V, Estep JD, Nissen SE, Wilson Tang WH, Starling RC. Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy. J Card Fail. 2021 03; 27(3):368-372.

View in: PubMed
McMurray JJV. Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? Kardiol Pol. 2021 01 25; 79(1):104-105.

View in: PubMed
Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, Barkoudah E, McMurray JJV, Pfeffer MA, Solomon SD. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC Heart Fail. 2021 01; 9(1):13-24.

View in: PubMed
Gillette M, Bozkurt B. Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. Ann Pharmacother. 2021 06; 55(6):805-813.

View in: PubMed
Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 10; 8(10):844-855.

View in: PubMed
Vaduganathan M, McMurray JJV, Solomon SD. Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. Eur J Heart Fail. 2020 09; 22(9):1525-1530.

View in: PubMed
Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, Zannad F, Chiang LM, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJV, Solomon SD, Zile MR. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 08 04; 76(5):503-514.

View in: PubMed
Cunningham JW, Vaduganathan M, Claggett BL, McMurray JJV, Solomon SD. Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction. JACC Heart Fail. 2020 08; 8(8):698-699.

View in: PubMed

People

Explore

Similar Concepts

Top Journals